(Q34544816)

2 August 2017

1 reference

title

Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent (English)

1 reference

2 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

James F McLeod

1

1 reference

2 August 2017

publication date

1 January 2004

1 reference

Clinical Pharmacokinetics

2 August 2017

published in

1 reference

2 August 2017

volume

43

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

97-120

1 reference

Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus

2 August 2017

cites work

1 reference

12 December 2020

Pharmacokinetics of nateglinide in renally impaired diabetic patients

1 reference

12 December 2020

The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

1 reference

12 December 2020

Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus

1 reference

12 December 2020

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

12 December 2020

Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality

1 reference

12 December 2020

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

1 reference

12 December 2020

Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

1 reference

12 December 2020

Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

1 reference

12 December 2020

Meglitinide analogues in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM).

1 reference

12 December 2020

Pharmacokinetics and metabolism of nateglinide in humans.

1 reference

12 December 2020

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

1 reference

12 December 2020

A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.

1 reference

12 December 2020

Sulphonylureas and hypoglycaemia

1 reference

12 December 2020

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Nateglinide therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program

1 reference

12 December 2020

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

1 reference

12 December 2020

Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus

1 reference

12 December 2020

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

12 December 2020

Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide

1 reference

12 December 2020

Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent

1 reference

12 December 2020

Drug-induced hypoglycemia. A review of 1418 cases.

1 reference

12 December 2020

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

1 reference

12 December 2020

Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver

1 reference

12 December 2020

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

1 reference

12 December 2020

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

1 reference

12 December 2020

Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.

1 reference

12 December 2020

A new phase of insulin secretion. How will it contribute to our understanding of beta-cell function?

1 reference

12 December 2020

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control

1 reference

12 December 2020

Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.

1 reference

12 December 2020

Insulinotropic meglitinide analogues

1 reference

12 December 2020

Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus.

1 reference

12 December 2020

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

12 December 2020

No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers

1 reference

12 December 2020

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas

1 reference

12 December 2020

1 reference

12 December 2020

The continuing epidemics of obesity and diabetes in the United States

1 reference

12 December 2020

Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.

1 reference

12 December 2020

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Renal glucose production and utilization: new aspects in humans

1 reference

12 December 2020

Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus

1 reference

12 December 2020

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Diabetes trends in the U.S.: 1990-1998.

1 reference

12 December 2020

Comparison of the kinetics of glyburide and its active metabolites in humans

1 reference

12 December 2020

Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study

1 reference

12 December 2020

Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects

1 reference

12 December 2020

Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide

1 reference

12 December 2020

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

10.2165/00003088-200443020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1011066817

0 references

1 reference